COG-AEWS1031
| Clinical Trial Title | Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma |
| Trial Status | Closed to Enrollment |
| Start Date | 11/01/2010 |
| Location | randall-childrens-hospital-at-legacy-emanuel |
| Trial Type | Pediatric Cancer (Oncology) |
| Specific Condition | Ewing Sarcoma (Non-Metastatic) |
| Description | This randomized phase III trial studies combination chemotherapy to see how well it works compared to combination chemotherapy with topotecan hydrochloride in treating patients with non-metastatic extracranial Ewing sarcoma. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, etoposide, and topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective with topotecan hydrochloride in treating Ewing sarcoma. |
| Eligibility Criteria | Age less than or equal to 50 years Newly diagnosed, biopsy confirmed, extracranial, non-metastatic Ewing sarcoma or PNET (Primitive neuroectodermal tumor) of bone or soft tissue No prior chemotherapy or radiation therapy is allowed Adquate kidney, liver, and heart function |
| IRB Number | |
| Notes | https://clinicaltrials.gov/ct2/show/NCT01231906 Study status is: Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled. |
| Principal Investigator | Janice Olson, MD |
| Contact Name | Children's Cancer and Blood Disorders Program |
| Contact Phone | (503) 276-9300 |
| Contact Fax | |
| Contact E-Mail |
